PASGPassage Bio, Inc.

4.440USD-1.55%Mkt Cap: 14.29M $P/E:

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD c…